Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part V. Pediatric Differentiated Thyroid Cancer 2024
- Author:
Jung-Eun MOON
1
;
So Won OH
;
Ho-Cheol KANG
;
Bon Seok KOO
;
Keunyoung KIM
;
Sun Wook KIM
;
Won Woong KIM
;
Jung-Han KIM
;
Dong Gyu NA
;
Sohyun PARK
;
Young Joo PARK
;
Jun-Ook PARK
;
Ji-In BANG
;
Kyorim BACK
;
Youngduk SEO
;
Young Shin SONG
;
Seung Hoon WOO
;
Ho-Ryun WON
;
Chang Hwan RYU
;
Sang-Woo LEE
;
Eun Kyung LEE
;
Joon-Hyop LEE
;
Jieun LEE
;
Cho Rok LEE
;
Dong-Jun LIM
;
Jae-Yol LIM
;
Ari CHONG
;
Yun Jae CHUNG
;
Chae Moon HONG
;
Hyungju KWON
;
Young Ah LEE
;
Author Information
- Publication Type:REVIEW ARTICLES
- From:International Journal of Thyroidology 2024;17(1):193-207
- CountryRepublic of Korea
- Language:EN
- Abstract: Pediatric differentiated thyroid cancers (DTCs), mostly papillary thyroid cancer (PTC, 80-90%), are diagnosed at more advanced stages with larger tumor sizes and higher rates of locoregional and/or lung metastasis. Despite the higher recurrence rates of pediatric cancers than of adult thyroid cancers, pediatric patients demonstrate a lower mortality rate and more favorable prognosis. Considering the more advanced stage at diagnosis in pediatric patients, preoperative evaluation is crucial to determine the extent of surgery required. Furthermore, if hereditary tumor syndrome is suspected, genetic testing is required. Recommendations for pediatric DTCs focus on the surgical principles, radioiodine therapy according to the postoperative risk level, treatment and follow-up of recurrent or persistent diseases, and treatment of patients with radioiodine-refractory PTCs on the basis of genetic drivers that are unique to pediatric patients.
